title: NK-/T-cell lymphoma resembling hydroa vacciniforme with positive CD4 marker expression: a diagnostic difficulty.
abstract: A 35-year-old Chinese woman presented with a 2.5-year history of facial swelling in the left lower quadrant and a 10-month history of relapsing red papules and vesicles in the perioral area resembling hydroa vacciniforme. Histologically, a tissue biopsy showed a dense infiltration of medium-sized atypical lymphocytic cells expressing CD4 and CD56. A diagnosis of cutaneous NK-/T-cell lymphoma was made. The patient was treated with alpha-interferon, valaciclovir hydrochloride, and low-dose prednisone for 2 months. Her skin lesions and lymphoadenopathy resolved initially, but she succumbed to the disease shortly after starting chemotherapy treatment 11 months later. To our knowledge, this is the first case of CD4CD56 NK-/T-cell lymphoma with clinical features resembling hydroa vacciniforme.
authors.affiliation: Department of Dermatology, the Second Xiang Ya Hospital, Central South University, Changsha, China.
authors.forename: Guiying
authors.initials: G
authors.lastname: Zhang
authors.forename: Harrison X
authors.initials: HX
authors.lastname: Bai
authors.forename: Li
authors.initials: L
authors.lastname: Yang
authors.forename: Michael H
authors.initials: MH
authors.lastname: Ma
authors.forename: Yuwen
authors.initials: Y
authors.lastname: Su
authors.forename: Yangyang
authors.initials: Y
authors.lastname: Luo
authors.forename: Haiquan
authors.initials: H
authors.lastname: Wen
authors.forename: Qianjin
authors.initials: Q
authors.lastname: Lu
authors.forename: Rong
authors.initials: R
authors.lastname: Xiao
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage / Q000031:analogs & derivatives; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D015704:CD4 Antigens / Q000032:analysis*; D019002:CD56 Antigen / Q000032:analysis; D003937:Diagnosis, Differential; D017809:Fatal Outcome; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology; D006801:Humans; D006837:Hydroa Vacciniforme / Q000276:immunology* / Q000473:pathology; D007150:Immunohistochemistry; D016898:Interferon-alpha / Q000008:administration & dosage; D054391:Lymphoma, Extranodal NK-T-Cell / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology / Q000821:virology; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D014408:Biomarkers, Tumor; D015704:CD4 Antigens; D019002:CD56 Antigen; D016898:Interferon-alpha; C522918:NCAM1 protein, human; D014633:Valine; D000077483:Valacyclovir; D011241:Prednisone; D000212:Acyclovir